<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307784</url>
  </required_header>
  <id_info>
    <org_study_id>DRGS-2014-2015-165-6</org_study_id>
    <nct_id>NCT04307784</nct_id>
  </id_info>
  <brief_title>The Effects of Vitamin D3 Alone and in a Combination With Omega-3 on the Association of C-peptide With Glycemic Control</brief_title>
  <official_title>The Effects of Vitamin D3 Supplementation Alone and in a Combination With Omega-3 on the Association of C-peptide With Glycemic Control; A Randomized Controlled Trial in People With Vitamin D Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Science Private University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Applied Science Private University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Effects of Vitamin D3 alone and in a combination with omega-3 on the association of
      C-peptide with glycemic control
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data bout the effects of Vitamin D3 (VD3) alone and as a combination with omega-3 fatty
      acids (Omega-3FA) on the association between C-peptide (CP) and the glycated hemoglobin
      (HbA1c) is scarce, conflicting and nothing published in the literature review on the combined
      effect of VD3 and Omega-3FA as a combination on the association of CP with glycemic control.

      This study will be conducted to investigate the effects of (VD3) alone and as a combination
      with Omega-3FA on the association between CP as an insulin secretion marker, and glycemic
      control parameters represented by glycated Hemoglobin (HbA1c), on people with vitamin D
      deficiency (VDD).

      This randomized, placebo-controlled trial is designed to test the effects of (50,000 IU VD3/
      weekly) and (300mg omega-3FA/daily) separately and as a combination for eight weeks, on the
      serum levels of CP, 25-hydroxy vitamin D (25OHD) and HbA1c. this study will be carried out
      during winter on 120 healthy Jordanian males and females with VDD with age range (25-50)
      years. Fasting serum levels for 25OHD, CP, HbA1c, PTH, Calcium, Phosphate, ALT (Alanine
      aminotransferase) and Urea were assessed at baseline and at the end of the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">June 10, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration of 25-hydroxyvitamin D, C-peptide and HbA1C</measure>
    <time_frame>8 weeks</time_frame>
    <description>Concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of PTH and Calcium</measure>
    <time_frame>8 weeks</time_frame>
    <description>Concentration</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Vitamin D3 alone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with VD3 (50.000 IU/week)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omaga-3 alone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with (1000 mg) wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 and Omega-3 Combination, Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with 50.000 IU VD3 per week and 1000 mg wild salmon and fish oil complex (contains 300 mg of n-3FA) once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No intervention was given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VD3</intervention_name>
    <description>VD3 (50.000 IU/week) for 8 weeks</description>
    <arm_group_label>Vitamin D3 alone Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Omega-3FA</intervention_name>
    <description>Omaga-3FA (300 mg/day) for 8 weeks</description>
    <arm_group_label>Omaga-3 alone Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VD3 and Omega-3FA</intervention_name>
    <description>VD3 (50.000 IU/week) and (Omega-3FA 300 mg /day) for 8 weeks</description>
    <arm_group_label>Vitamin D3 and Omega-3 Combination, Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No intervention is given</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>nothing</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged (30-64)

          -  Have a medical diagnosis of VDD

        Exclusion Criteria:

          -  Chronic diseases, such as (osteoporosis, cancer, kidney disease(due to the association
             between prolonged administration of VD3 and kidney stones formation), an endocrine
             disorder, thalassemia).

          -  Documented history of allergic reactions to Omega-3FA supplementations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud S Abu-samak, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Applied Science Private University (ASU)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Applied Science University</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/25648391</url>
    <description>C-peptide: new findings and therapeutic possibilities.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitamin D Deficiency</keyword>
  <keyword>vitamin D3</keyword>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>glycated Hemoglubine</keyword>
  <keyword>C-peptide</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>VD3</keyword>
  <keyword>A1C</keyword>
  <keyword>HbA1C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underline results in a publication.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>When summary data are published</ipd_time_frame>
    <ipd_access_criteria>Open access</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

